È«Çò¸ß´ï4ÒÚ¶àÈ˱¥ÊÜÌÇÄò²¡À§ÈÅ£¬ÆäÖÐÎÒ¹úÌÇÄò²¡»¼²¡ÈËÊý¾ÓÈ«ÇòÖ®Ê×£¬Òѳ¬1.3 ÒÚ£¬Õ¼ÌìÏÂ×ÜÉú³ÝµÄ 9.4%[1]¡£ÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ壨glucagon-like peptide-1 receptor, GLP-1R£©ÊÇÖÎÁÆ2ÐÍÌÇÄò²¡×îÓÐÓõİеãÖ®Ò»¡£
ͼ1 È«ÇòÌÇÄò²¡»¼Õßͳ¼Æ
×òÈÕ£¨8ÔÂ18ÈÕ£©ÐÅ´ïÉúÎïµÄÐÂÐÍGLP-1R/GCGRË«¼¤¶¯¼ÁIBI362 (LY3305677)Ò»ÆÚÁÙ´²Ð§¹ûÔÚ¹ú¼Ê×ÅÃûÆÚ¿¯ÁøÒ¶µ¶×Ó¿¯EClinicalMedicineÉϽÒÏþ¡£½ñÄê4Ô£¬ÅµºÍŵµÂµÄGLP-1R¼¤¶¯¼Á¶àëÄ˾ÃÀ¸ñ³ëÄ×¢ÉäÒºÔÚº£ÄÚÉÏÊУ¬Ã¿ÖÜÖ»ÐèƤÏÂ×¢Éä1´Î¡£ÏÖÔÚº£ÄÚÉÏÊеÄGLP-1R¼¤¶¯¼ÁÀàÒ©ÎïµÖ´ï8¿î£¬ËüÃDz»µ«½µÌÇЧ¹ûÏÔÖø£¬Í¬Ê±»¹¼æ¾ß¼õÖØ¡¢½µÑ¹¡¢¸ÄÉÆѪ֬Æ×µÈ×÷Ó᣽üÄêÀ´GLP-1R¼¤¶¯¼ÁÀàÒ©ÎïÊг¡¹æÄ£Ò»Ö±ÔöÌí£¬2020ÄêÈ«ÇòÊг¡¹æÄ£ÒÑ´ï100ÒÚÃÀÔª¡£
GLP-1RΪºÎÄÜÔÚ2ÐÍÌÇÄò²¡ÖÎÁÆÉÏ´ó·ÅÒì²Ê£¬½ñÌìС±à´ø¸÷ÈËһ̽ÊÂʵ¡£
GLP-1R¼ò½é
GLP-1RÊôÓÚGÂÑ°×żÁªÊÜÌåB´ØÖÐÒȸßѪÌÇËØÊÜÌåÑǼÒ×壬ËüµÄµä·¶ÌØÕ÷ÊǾßÓÐÒ»¸öÆߴοçĤµÄ½¹µãÓòºÍÒ»¸öÏà¶Ô½ÏÁ¿´óµÄ°ûÍâÓò[2]¡£È˵ÄGLP-1R»ùÒòλÓÚµÚ6ºÅȾɫÌåÉÏ£¬±àÂë463¸ö°±»ùËá¡£ÒÈÏÙÄÚµÄGLP-1RÖ÷Òª±í´ïÔÚÒȵº¦Âϸ°ûÖУ¬³ýÒȵºÍ⣬GLP-1R»¹ÆÕ±é±í´ïÓÚθ¡¢Ð¡³¦¡¢ÐÄÔà¡¢ÉöÔà¡¢·Î¼°´óÄÔµÈ×éÖ¯Æ÷¹ÙÖÐ[3]¡£¹ËÃû˼Ò壬GLP-1RµÄÖ÷Òª×÷ÓÃÊǺÍÒȸßѪÌÇËØÑùëÄ-1£¨glucagon-like peptide-1 receptor, GLP-1£©ÍŽᣬµ÷ÀíѪÌÇ¡£
ͼ2 GLP-1R¿çĤÇøÈýά½á¹¹
GLP-1
GLP-1ÊÇÒ»ÖÖÖ÷ÒªÓɳ¦µÀLϸ°ûËù±¬·¢µÄ¼¤ËØ£¬ÊôÓÚ³¦´ÙÒÈËØ¡£GLP-1µÄ°ëË¥ÆÚºÜÊǶ̣¬½ö1-2min£¬ÆäÊ©Õ¹ÐÄÀí¹¦Ð§Ö÷ÒªÊÇͨ¹ýÍŽᲢ¼¤»îGLP-1R¡£ÈËÌåÄÚ³¦´ÙÒÈËسýGLP-1ÍâÉÐÓÐÆÏÌÑÌÇÒÀÀµÐÔÒȵºËØÊÍ·ÅëÄ£¨GIP£©£¬¿ÉÊÇÖ»ÓÐGLP-1¿ÉÒÔÒÖÖÆÒȸßѪÌÇËصÄÊÍ·Å£¬ÒýÆð±¥×ã¸Ð[4]¡£×èÖ¹µ½2021Ä꣬ÁÙ´²Éϳ¦´ÙÒÈËØÀàÒ©Îï¾ù»ùÓÚGLP-1¡£
GLP-1RµÄ¹¦Ð§
GLP-1RÆÕ±éÂþÑÜÔÚÒȵº¡¢Î¸¡¢Ð¡³¦¡¢ÐÄÔà¡¢ÉöÔà¡¢·Î¡¢´óÄÔµÈ×éÖ¯Æ÷¹ÙÖУ¬µ±Ëü±»GLP-1ijÈ˹¤ºÏ³ÉµÄGLP-1R¼¤¶¯¼Á¼¤»îºó£¬±ãÄÜÊ©Õ¹¶àÖÖ²î±ðµÄÐÄÀí¹¦Ð§¡£ÔÚÒȵºÏ¸°ûÖУ¬GLP-1RµÄÖ÷Òª×÷ÓÃÊÇÔö½øÒȵº¦Âϸ°ûµÄÔöÖ³£¬´Ì¼¤ÒȵºËصĺϳÉÓëÊÍ·Å£¬²¢ÒÖÖÆÒȸßѪÌÇËصĺϳÉÓëÊÍ·Å¡£ÔÚ賦µÀµÈ×éÖ¯ÖУ¬GLP-1R¿ÉÒÔÒÖÖÆθҺÉø͸ºÍ賦µÀµÄÈ䶯£¬ÑÓ³ÙθµÄÅÅ¿Õ£¬ÔöÌí÷ÐâÀ¸Ð£¬ïÔÌʳÎïÉãÈ¡[4]¡£ÔÚÉñ¾×éÖ¯ÖУ¬GLP-1R¿ÉÒÔ±£»¤Éñ¾Ï¸°û£¬¶Ô¿¹Ê³Óû²»Õñ£¬ÔöÇ¿Ó°ÏóÁ¦¡£ÔÚÐÄѪ¹Ü·½Ã棬GLP-1R¿ÉÒÔÌáÉýÐÄѪ¹ÜµÄ¹¦Ð§£¬ïÔÌÑ×Ö¢[5]¡£
ͼ3 GLP-1RµÄÐÄÀí¹¦Ð§
GLP-1RµÄ¼¤»î
GLP-1RÓëÅäÌåµÄÍŽ᷽·¨Ö÷ÒªÊǸ÷ÈËÊìÖªµÄ¡°two-domain model¡±¡£ÅäÌåµÄC¶ËÏÈͬGLP-1RµÄ°ûÍâÓòÍŽᣬʹGLP-1RµÄ¿Õ¼ä¹¹Ï󱬷¢¸Ä±ä£¬Ì»Â¶³ö½¹µãÓòµÄÍŽáλµã£¬È»ºóÅäÌåµÄN¶ËͬGLP-1RµÄ½¹µãÓòÍŽᣬ¼¤»îGLP-1R¡£Ò»Ñùƽ³£À´Ëµ£¬GLP-1R°ûÍâÓòµÄÖ÷Òª×÷ÓÃÊÇʶ±ðÌØÒìÐÔµÄÅäÌ壬¶ø½¹µãÓòÔòÔÚÐźÅÌØÒìÐÔ´«µ¼ÖÐÊ©Õ¹Ö÷Òª×÷ÓÃ[6]¡£
ͼ4 GLP-1RÓëÅäÌåÍŽáµÄģʽͼ
GLP-1RÐźÅתµ¼µ÷¿Ø»úÖÆ
GLP-1RÊÇÒ»ÖÖ¶àЧÐÔżÁªÊÜÌ壬Ö÷Ҫͨ¹ýÓë¶àÖÖGÂÑ°×£¨G¦Ás¡¢G¦Ái¡¢G¦ÁoºÍG¦Áq/11£©Å¼ÁªÀ´µ÷¿Øϸ°ûͨ·¡£µ±ÓëGLP-1ÍŽáºó£¬GLP-1RÔÚÒȵº¦Âϸ°ûÖÐżÁªG¦ÁsÂÑ°×£¬¼¤»îÏÙÜÕ»·»¯Ã¸£¬´ÙʹcAMPÔÚϸ°ûÄÚº¬Á¿Éý¸ß£¬ÒýÆð¸ÆÀë×ÓÄÚÁ÷£¬ÒȵºËØÔ»ùÒòת¼ÔöÌí£¬´Ì¼¤ÑªÌÇÒÀÀµÐÔÒȵºËصÄÉø͸[7]¡£³ý´ËÖ®Í⣬GLP-1R»¹¿ÉÒÔͨ¹ý¼¤»îPI3K¡¢MAPKºÍRas/MAPKÐźÅͨ·À´Ôö½øÒȵº¦Âϸ°ûµÄÔöÖ³ºÍ·Ö½â¡£²»µ«ÔÆÔÆ£¬GLP-1R»¹Äܹ»Í¨¹ýµ÷¿ØcAMP·´Ó¦Ôª¼þÍŽáÂÑ°×£¨CREB£©ºÍÂѰ׸´ÉúÒò×ÓBcl-2¡¢Bcl-XLµÈÀ´ÒÖÖÆϸ°ûµòÍö[8]¡£
ͼ5 Òȵº¦Âϸ°ûÖÐGLP-1Rµ÷¿ØµÄÐźÅͨ·
С·Ö×Ó·ÇëÄÀàGLP-1R¼¤¶¯¼Á
2019ÄêŵºÍŵµÂÐû²¼FDAÅú×¼Æä¿Ú·þË÷Âí³ëÄ£¨ÉÌÆ·ÃûRybelsus£©ÉÏÊУ¬³ÉΪȫÇòÊ׿î¿Ú·þGLP-1R¼¤¶¯¼Á¡£¿Ú·þË÷Âí³ëĵķºÆðÍ»ÆÆÁËÌÇÄò²¡»¼ÕßÐèÒªÌìÌì»òÿÖÜ×¢ÉäÒ©ÎïµÄÏÖ×´£¬±¸ÊÜÊг¡¹Ø×¢£¬ÏÆÆðÁËС·Ö×Ó·ÇëÄÀàGLP-1R¼¤¶¯¼ÁÒ©ÎïµÄÑз¢Å³±£¡
±í1 ÔÚÑÐС·Ö×ÓGLP-1R¼¤¶¯¼Á
GLP-1RÈËÔ´»¯Ð¡Êó
¼øÓÚGLP-1RÔÚ2ÐÍÌÇÄò²¡Ò©Î↑·¢ÖеÄÖ÷Òª×÷Óã¬ÉϺ£ÄÏ·½Ä£Ê½ÉúÎï¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾£¨Shanghai Model Organisms Center£¬Inc.£¬¼ò³Æ¡°ÄÏÄ£ÉúÎ£©×ÔÖ÷Ñз¢ÁËGLP-1RÈËÔ´»¯Ð¡ÊóÄ£×Ó£¬ÎªÌÇÄò²¡Ò©Îïɸѡ£¬Ïà¹ØҩЧʵÑéµÈÑо¿ÌṩÁËÇ¿ÓÐÁ¦µÄ¹¤¾ß¡£
½µÑªÌÇҩЧÑéÖ¤
GLP-1RÈËÔ´»¯Ð¡Êó£¬ÔÚ¸øÒ©ºÍ²»¸øÒ©µÄÌõ¼þϾÙÐпڷþÌÇÄÍÁ¿£¨OGTT£©ÊµÑ飨n=5£©¡£
ͼ6 OGTTʵÑ飨ÑéÖ¤Êý¾ÝÓÉ¿Í»§Ìṩ£©
Ч¹ûÏÔʾ£ºÕë¶ÔÈËÔ´GLP-1R£¬´ý²â»¯ºÏÎïÌåÏÖ³öºÜºÃµÄ½µÑªÌÇЧ¹û£¨p<0.001£©¡£ÉÏÊöÊý¾Ý֤ʵ£¬GLP-1RÈËÔ´»¯Ð¡ÊóÄ£×Ó£¬ÊǾÙÐÐÌÇÄò²¡Ò©ÎïɸѡµÄÓÐÓù¤¾ß¡£
ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼ÁìÓò£¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ£¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ£¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£
Reference:
[1]¹ú¼ÊÌÇÄò²¡Í¬ÃË IDF 2019È«ÇòÌÇÄò²¡µØͼ(µÚ9°æ)
[2]Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery, 2012, 11 : 603¨C619.
[3]Pabreja K, Mohd MA, Koole C, et al. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. British Journal of Pharmacology, 2014, 171 : 1114¨C1128. DOI:10.1111/bph.12313
[4]Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors & Channels, 2011, 8 : 179¨C188.
[5]Laviola L, Leonardini A, Melchiorre M, et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology, 2012, 153 : 5770¨C5781. DOI:10.1210/en.2012-1461
[6]ºúÖÐƽ, ³ÌÄî, Ñî·«, ËÕÕý¶¨. GLP-1R½á¹¹ºÍ¹¦Ð§¼°Ð¡·Ö×ÓÒ©ÎïɸѡÑо¿Ï£Íû[J]. ÉúÎïÊÖÒÕת´ï, 2017, 33(2): 30-40
[7]Dalle S, Ravier MA, Bertrand G. Emerging roles for ¦Â-arrestin-1 in the control of the pancreatic ¦Â-cell function and mass: New therapeutic strategies and consequences for drug screening. Cellular Signalling, 2011, 23 : 522¨C528. DOI:10.1016/j.cellsig.2010.09.014
[8]Robert G, Xiaomang Y, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology, 2003, 144 : 2242¨C2252. DOI:10.1210/en.2003-0007